98 related articles for article (PubMed ID: 31494077)
1. Enantiomer of the novel flexible heteroarotinoid, SL-1-09, blocks cell cycle progression in breast cancer cells.
Ginn E; Baek J; Zou H; Fallatah MMJ; Liu S; Sevigny MB; Louie M
Eur J Pharmacol; 2019 Nov; 862():172634. PubMed ID: 31494077
[TBL] [Abstract][Full Text] [Related]
2. Novel flexible heteroarotinoid, SL-1-18, promotes ERα degradation to inhibit breast cancer cell growth.
Fallatah MM; Liu S; Sevigny MB; Zou H; Louie MC
Cancer Lett; 2017 Nov; 408():82-91. PubMed ID: 28844711
[TBL] [Abstract][Full Text] [Related]
3. Novel flexible heteroarotinoid, SL-1-39, inhibits HER2-positive breast cancer cell proliferation by promoting lysosomal degradation of HER2.
Zou H; Sevigny MB; Liu S; Madden DT; Louie MC
Cancer Lett; 2019 Feb; 443():157-166. PubMed ID: 30503556
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of second generation Flex-Het scaffolds against the human ovarian cancer A2780 cell line.
Gnanasekaran KK; Benbrook DM; Nammalwar B; Thavathiru E; Bunce RA; Berlin KD
Eur J Med Chem; 2015; 96():209-17. PubMed ID: 25880346
[TBL] [Abstract][Full Text] [Related]
5. Development of flexible-heteroarotinoids for kidney cancer.
Liu T; Masamha CP; Chengedza S; Berlin KD; Lightfoot S; He F; Benbrook DM
Mol Cancer Ther; 2009 May; 8(5):1227-38. PubMed ID: 19417155
[TBL] [Abstract][Full Text] [Related]
6. Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor agonists.
Benbrook DM; Kamelle SA; Guruswamy SB; Lightfoot SA; Rutledge TL; Gould NS; Hannafon BN; Dunn ST; Berlin KD
Invest New Drugs; 2005 Oct; 23(5):417-28. PubMed ID: 16133793
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of SHetA2 (NSC-721689) analogs against the ovarian cancer cell line A2780.
Nammalwar B; Bunce RA; Berlin KD; Benbrook DM; Toal C
Eur J Med Chem; 2019 May; 170():16-27. PubMed ID: 30878829
[TBL] [Abstract][Full Text] [Related]
8. Tetrahydroquinoline units in flexible heteroarotinoids (Flex-Hets) convey anti-cancer properties in A2780 ovarian cancer cells.
Gnanasekaran KK; Pouland T; Bunce RA; Darrell Berlin K; Abuskhuna S; Bhandari D; Mashayekhi M; Zhou DH; Benbrook DM
Bioorg Med Chem; 2020 Jan; 28(1):115244. PubMed ID: 31831296
[TBL] [Abstract][Full Text] [Related]
9. Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo.
Myers T; Chengedza S; Lightfoot S; Pan Y; Dedmond D; Cole L; Tang Y; Benbrook DM
Invest New Drugs; 2009 Aug; 27(4):304-18. PubMed ID: 18802666
[TBL] [Abstract][Full Text] [Related]
10. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
[TBL] [Abstract][Full Text] [Related]
11. CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells.
Lin YD; Chen S; Yue P; Zou W; Benbrook DM; Liu S; Le TC; Berlin KD; Khuri FR; Sun SY
Cancer Res; 2008 Jul; 68(13):5335-44. PubMed ID: 18593935
[TBL] [Abstract][Full Text] [Related]
12. Activity of oxygen-versus sulfur-containing analogs of the Flex-Het anticancer agent SHetA2.
Watts FM; Pouland T; Bunce RA; Berlin KD; Benbrook DM; Mashayekhi M; Bhandari D; Zhou D
Eur J Med Chem; 2018 Oct; 158():720-732. PubMed ID: 30245396
[TBL] [Abstract][Full Text] [Related]
13. The synthetic heteroarotinoid SHetA2 induces apoptosis in squamous carcinoma cells through a receptor-independent and mitochondria-dependent pathway.
Chun KH; Benbrook DM; Berlin KD; Hong WK; Lotan R
Cancer Res; 2003 Jul; 63(13):3826-32. PubMed ID: 12839980
[TBL] [Abstract][Full Text] [Related]
14. A novel taspine derivative, HMQ1611, inhibits breast cancer cell growth via estrogen receptor α and EGF receptor signaling pathways.
Zhan Y; Zhang Y; Liu C; Zhang J; Smith WW; Wang N; Chen Y; Zheng L; He L
Cancer Prev Res (Phila); 2012 Jun; 5(6):864-73. PubMed ID: 22496388
[TBL] [Abstract][Full Text] [Related]
15. Furanodienone inhibits cell proliferation and survival by suppressing ERα signaling in human breast cancer MCF-7 cells.
Li YW; Zhu GY; Shen XL; Chu JH; Yu ZL; Fong WF
J Cell Biochem; 2011 Jan; 112(1):217-24. PubMed ID: 21069738
[TBL] [Abstract][Full Text] [Related]
16. Discovery of coumarin-monastrol hybrid as potential antibreast tumor-specific agent.
Sashidhara KV; Avula SR; Sharma K; Palnati GR; Bathula SR
Eur J Med Chem; 2013 Feb; 60():120-7. PubMed ID: 23287057
[TBL] [Abstract][Full Text] [Related]
17. Involvement of c-FLIP and survivin down-regulation in flexible heteroarotinoid-induced apoptosis and enhancement of TRAIL-initiated apoptosis in lung cancer cells.
Lin Y; Liu X; Yue P; Benbrook DM; Berlin KD; Khuri FR; Sun SY
Mol Cancer Ther; 2008 Nov; 7(11):3556-65. PubMed ID: 19001438
[TBL] [Abstract][Full Text] [Related]
18. Hydrogen sulfide-releasing aspirin suppresses NF-κB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo.
Chattopadhyay M; Kodela R; Nath N; Barsegian A; Boring D; Kashfi K
Biochem Pharmacol; 2012 Mar; 83(6):723-32. PubMed ID: 22209867
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of 3-aryl-quinolin derivatives as anti-breast cancer agents targeting ERα and VEGFR-2.
Li X; Wu C; Lin X; Cai X; Liu L; Luo G; You Q; Xiang H
Eur J Med Chem; 2019 Jan; 161():445-455. PubMed ID: 30384047
[TBL] [Abstract][Full Text] [Related]
20. High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2.
Zhang Y; Hua Y; Benbrook DM; Covey JM; Dai G; Liu Z; Chan KK
Cancer Chemother Pharmacol; 2006 Nov; 58(5):561-9. PubMed ID: 16534614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
